Autolus Therapeutics plc
Autolus Therapeutics plc is a biopharmaceutical company focused on developing and commercializing programmed T-cell therapies, with its first approved product, AUCATZYL, now generating U.S. product revenue. The company’s core platform is CAR T-cell engineering, which it uses to design therapies for hematologic cancers and to advance a broader pipeline of product candidates. Autolus also relies on translational research collaborations, including with University College London, to support early-stage development. The business remains in an investment-and-launch phase, with commercial execution in the U.S. alongside ongoing clinical development and manufacturing scale-up in the U.K.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueApproved CAR T therapy sold in the U.S. for eligible cancer patients.
Investigational CAR T programs advancing through preclinical and clinical development.
Research collaborations and license arrangements that support pipeline creation and development.
Cell therapy manufacturing, release, and distribution activities supporting commercial and clinical supply.
Products
Reported · share of revenue- Products98.5 %
- License1.5 %
Source: 10-K FY2025, revenue the company reports per product line (SEC XBRL). Shares are of the lines shown and add up to 100 %.
Customers
Autolus sells AUCATZYL through U.S. cancer treatment centers, so its direct customers are healthcare providers and treatment centers rather than retail patients. The therapy is used in oncology settings where physicians and hospital systems decide on treatment pathways for eligible patients with serious blood cancers. Reimbursement and access are important because the company’s revenue depends on coverage from commercial and government payors, including Medicaid, TriCare, DoD, VA, and 340B-related channels. As the launch expands, the company’s customer base is defined by activated treatment centers and the patients they serve, with access and formulary coverage shaping adoption.
Hospitals and oncology centers buy and administer AUCATZYL for eligible patients; they matter because the therapy is delivered through activated sites of care.
Commercial insurers and programs such as Medicaid, TriCare, DoD, VA, and 340B influence coverage, reimbursement, and net realized pricing.
Specialists choose CAR T therapy for patients based on clinical profile, access, and treatment pathway suitability.
Patients are the end beneficiaries of the therapy; demand depends on diagnosis, eligibility, and access to treatment centers.
Strategy
Autolus is focused on converting AUCATZYL from launch into a scaled commercial franchise in the United States while continuing to advance its CAR T pipeline. A key priority is expanding the number of activated cancer treatment centers and broadening coverage so more patients can access therapy. The company is also investing in manufacturing, supply chain reliability, and commercial execution because cell therapies require tightly controlled production and distribution. At the same time, management continues to use collaborations and licensing to support early-stage development while preserving capital for later-stage programs.
Commercial success depends on center activation, patient access, and reimbursement coverage.
CAR T therapies are operationally complex and require reliable commercial and clinical supply.
Long-term value depends on additional product candidates and broader platform validation.
Geography
Autolus currently generates product revenue in the United States, where AUCATZYL has been launched and where the company has been expanding activated treatment centers. The company also manufactures all commercial supplies of AUCATZYL and clinical supplies of other product candidates in the United Kingdom, making the U.K. a critical operating base even though near-term revenue there is small. Management has stated that U.K. customer revenue is expected to remain a small proportion of overall activity, but U.K. VAT treatment still affects cash taxes and recoverability of input VAT. The business therefore has a U.S. commercial footprint combined with a U.K.-centered manufacturing and development footprint, plus international sourcing exposure through its supply chain.
Risks
Autolus faces the typical risks of a cell-therapy company: clinical development uncertainty, manufacturing complexity, reimbursement pressure, and dependence on a small number of products. The company’s revenue is currently concentrated in AUCATZYL, so launch execution, payer coverage, and treatment-center adoption have an outsized effect on results. It also relies on a global supply chain and U.K.-based manufacturing, which exposes it to tariffs, trade restrictions, and foreign supplier disruption. In addition, product revenue is reduced by rebates, chargebacks, and government-program pricing, making net sales sensitive to estimation uncertainty and policy changes in healthcare reimbursement.
- Reimbursement and pricing pressureImpact: HighLikelihood: High
Coverage decisions, government program pricing, and rebate/chargeback mechanics directly reduce net product revenue.
Exposure - Manufacturing and supply chain disruptionImpact: HighLikelihood: High
CAR T products require specialized materials, outsourced services, and controlled manufacturing, which can be interrupted or become more expensive.
Exposure: U.K. manufacturing and global suppliers
- AUCATZYL launch concentrationImpact: High
The company currently depends on a single commercial product, so slower adoption or access issues would materially affect revenue.
Exposure: U.S. commercial launch
- Clinical pipeline failureImpact: High
Future value depends on successful development of additional product candidates, which may not reach approval.
Exposure: Preclinical and clinical CAR T programs
- International trade policy and tariffsImpact: MediumLikelihood: High
Tariffs or export restrictions could increase cost of goods and delay commercial or clinical supply.
Exposure: Cross-border sourcing and U.S. import flows
Accounting
Judgemental itemsRevenue is recognized when AUCATZYL is administered and the return/refund constraint lapses, so timing depends on treatment events rather than shipment.
Impact: Can shift revenue between quarters and affect comparability.
Rebates, chargebacks, patient assistance, Medicaid, TriCare, DoD, VA, and 340B pricing reduce net sales and require estimation.
Impact: Directly affects reported product revenue and accrued liabilities.
Pre-approval production costs were recorded in R&D, while post-approval costs flow through cost of sales.
Impact: Distorts gross margin trends across launch periods.
The company records liabilities for expected deductions and updates them as claims data becomes available.
Impact: Creates balance-sheet sensitivity to estimate changes.
Similar listed companies
Publicly listed companies with a comparable business focus.
Aclaris Therapeutics, Inc.
ACRS · Pharmaceutical Preparations
Aclaris Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing small and large molecule therapies for immuno-inflammatory diseases.
Arcellx, Inc.
Biological Products, (No Diagnostic Substances)
Atara Biotherapeutics, Inc.
ATRA · Biological Products, (No Diagnostic Substances)
Atara Biotherapeutics is a U.S.-based biotechnology company focused on T-cell immunotherapy built around its allogeneic Epstein-Barr virus (EBV) T-cell platform.
BioAtla, Inc.
BCAB · Biological Products, (No Diagnostic Substances)
Cartesian Therapeutics, Inc.
RNAC · Pharmaceutical Preparations
Vera Therapeutics, Inc.
VERA · Pharmaceutical Preparations
Last updated: 24/09/2026